BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 238 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2024. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $17,168,251 | -49.9% | 3,379,577 | -40.9% | 0.55% | -56.0% |
| Q4 2023 | $34,253,677 | -9.8% | 5,718,477 | +6.6% | 1.26% | +4.8% |
| Q3 2023 | $37,969,898 | +93.2% | 5,362,980 | +92.1% | 1.20% | +86.9% |
| Q2 2023 | $19,654,835 | +21.2% | 2,791,880 | +43.5% | 0.64% | +20.0% |
| Q1 2023 | $16,222,418 | – | 1,945,134 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $50,998,000 | 20.86% |
| RTW INVESTMENTS, LP | 3,458,120 | $29,048,000 | 7.65% |
| ISZO CAPITAL MANAGEMENT LP | 307,366 | $2,582,000 | 4.49% |
| DAFNA Capital Management LLC | 541,128 | $4,545,000 | 3.84% |
| RA Capital Management | 3,489,795 | $29,314,000 | 3.60% |
| EMORY UNIVERSITY | 375,348 | $3,153,000 | 2.98% |
| Ghost Tree Capital, LLC | 1,500,000 | $12,600,000 | 2.35% |
| ACUTA CAPITAL PARTNERS, LLC | 920,310 | $7,731,000 | 1.83% |
| Avoro Capital Advisors LLC | 1,603,001 | $13,465,000 | 1.72% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,085,236 | $25,916,000 | 1.00% |